/SOPH
SOPH Stock - SOPHiA GENETICS S.A.
Healthcare|Medical - Healthcare Information ServicesNASDAQ
$4.61-2.54%
$0.12 (-2.54%) • Dec 19
70
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.84
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).67
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.76
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+8.5%upside
Target: $5.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for SOPH
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$4.56 – $4.66
TARGET (TP)$5.00
STOP LOSS$4.24
RISK/REWARD1:1.1
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.11
52W High$5.30
52W Low$2.58
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $65.17M | $62.37M | $47.56M | $40.45M | $28.40M |
| Gross Profit | $43.94M | $42.91M | $31.25M | $25.22M | $17.69M |
| Gross Margin | 67.4% | 68.8% | 65.7% | 62.4% | 62.3% |
| Operating Income | $-66,568,000 | $-74,826,000 | $-87,823,000 | $-71,489,000 | $-37,387,000 |
| Net Income | $-62,493,000 | $-78,981,000 | $-87,449,000 | $-73,675,000 | $-39,339,000 |
| Net Margin | -95.9% | -126.6% | -183.9% | -182.1% | -138.5% |
| EPS | $-0.95 | $-1.22 | $-1.36 | $-1.33 | $-0.82 |
Company Overview
SOPHiA GENETICS SA operates as a healthcare technology company. The company offers SOPHiA DDM platform, a cloud-based software-as-a-service platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, products, and services are used by hospital, laboratory, and biopharma worldwide. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Saint-Sulpice, Switzerland.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
4
67%
Hold / Neutral
2
33%
Sell / Underperform
0%
Analyst Consensus🟡 Mixed
4 Bullish2 Neutral/Bearish
Price Targets
$7
Average Target
↑ 48.7% Upside
Now
$2
Low
$7
Average
$11
High
Based on 7 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 18th 2024 | Craig Hallum | Initiation | Buy | $11 |
| August 7th 2024 | Morgan Stanley | Downgrade | Equal Weight | $5← $10 |
| June 27th 2024 | Guggenheim | Initiation | Buy | $6 |
| November 29th 2023 | RBC Capital Mkts | Initiation | Outperform | $8 |
| July 5th 2023 | JP Morgan | Resumed | Overweight | $10 |
| January 3rd 2023 | BTIG Research | Initiation | Buy | $6 |
| November 23rd 2022 | Credit Suisse | Initiation | Neutral | $2 |
Earnings History & Surprises
SOPHBeat Rate
44%
Last 18 quarters
Avg Surprise
+11.2%
EPS vs Estimate
Beats / Misses
8/8
2 met exactly
Latest EPS
$-0.30
Q4 2025
EPS Surprise History
Q1 24
-48.0%
$-0.37vs$-0.25
Q2 24
+16.0%
$-0.21vs$-0.25
Q3 24
+17.9%
$-0.23vs$-0.28
Q4 24
-16.7%
$-0.28vs$-0.24
Q1 25
0.0%
$-0.23vs$-0.23
Q2 25
-23.8%
$-0.26vs$-0.21
Q3 25
+257.1%
$0.33vs$-0.21
Q4 25
-50.0%
$-0.30vs$-0.20
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 4, 2026 | — | — | — | — |
Q4 2025 | Nov 4, 2025 | $-0.20 | $-0.30 | -50.0% | ✗ MISS |
Q3 2025 | Aug 5, 2025 | $-0.21 | $0.33 | +257.1% | ✓ BEAT |
Q2 2025 | May 6, 2025 | $-0.21 | $-0.26 | -23.8% | ✗ MISS |
Q1 2025 | Mar 4, 2025 | $-0.23 | $-0.23 | 0.0% | = MET |
Q4 2024 | Nov 5, 2024 | $-0.24 | $-0.28 | -16.7% | ✗ MISS |
Q3 2024 | Aug 6, 2024 | $-0.28 | $-0.23 | +17.9% | ✓ BEAT |
Q2 2024 | May 7, 2024 | $-0.25 | $-0.21 | +16.0% | ✓ BEAT |
Q1 2024 | Mar 5, 2024 | $-0.25 | $-0.37 | -48.0% | ✗ MISS |
Q4 2023 | Nov 7, 2023 | $-0.32 | $-0.21 | +34.4% | ✓ BEAT |
Q3 2023 | Aug 8, 2023 | $-0.29 | $-0.33 | -13.8% | ✗ MISS |
Q2 2023 | May 9, 2023 | $-0.28 | $-0.31 | -10.7% | ✗ MISS |
Q1 2023 | Mar 7, 2023 | $-0.34 | $-0.22 | +35.3% | ✓ BEAT |
Q4 2022 | Nov 8, 2022 | $-0.34 | $-0.36 | -5.9% | ✗ MISS |
Q3 2022 | Aug 9, 2022 | $-0.39 | $-0.39 | 0.0% | = MET |
Q2 2022 | May 10, 2022 | $-0.33 | $-0.40 | -21.2% | ✗ MISS |
Q1 2022 | Mar 15, 2022 | $-0.34 | $-0.33 | +2.9% | ✓ BEAT |
Q4 2021 | Nov 10, 2021 | $-0.38 | $-0.35 | +7.9% | ✓ BEAT |
Q3 2021 | Sep 9, 2021 | $-0.39 | $-0.31 | +20.5% | ✓ BEAT |
Q3 2021 | Jul 23, 2021 | — | $-0.26 | — | — |
Latest News
SOPHiA GENETICS And Element Biosciences Announce Partnership Integrating SOPHiA GENETICS' SOPHiA DDM Platform With Element's Sequencing Systems
📈 PositiveBenzinga•Nov 11, 2025, 01:02 PM
BTIG Maintains Buy on Sophia Genetics, Raises Price Target to $7
📈 PositiveBenzinga•Nov 10, 2025, 09:52 AM
Sophia Genetics Raises FY2025 Sales Guidance from $72.000M-$76.000M to $75.000M-$77.000M vs $74.500M Est
📈 PositiveBenzinga•Nov 4, 2025, 11:26 AM
Sophia Genetics Q3 EPS $(0.30) Misses $(0.23) Estimate, Sales $19.462M Beat $18.125M Estimate
➖ NeutralBenzinga•Nov 4, 2025, 11:25 AM
SOPHiA GENETICS And A.D.A.M. Innovations Partner To Launch AI-Powered Liquid Biopsy Genomic Testing And Develop Companion Diagnostic For Cancer Care In Japan
📈 PositiveBenzinga•Oct 16, 2025, 03:02 PM
SOPHiA GENETICS Unveils AI-Driven Digital Twins To Advance Precision And Decision-Making In Oncology
📈 PositiveBenzinga•Oct 16, 2025, 08:12 AM
Myriad Genetics And SOPHiA GENETICS Collaborate To Develop And Provide Pharmaceutical Companies With Innovative Global Liquid Biopsy Companion Diagnostic Test
📈 PositiveBenzinga•Sep 23, 2025, 12:02 PM•Also:
SOPHiA GENETICS Expands AstraZeneca Collaboration, SOPHiA To Roll Out Privileged Access Program To Selected Labs Specializing In Breast And Prostate Cancer Research
📈 PositiveBenzinga•Sep 22, 2025, 12:13 PM•Also:
SOPHiA GENETICS And Jessa Ziekenhuis Collaborate To Advance Data-Driven Precision Oncology With Cloud-Native Genomic Platform Integration
📈 PositiveBenzinga•Sep 5, 2025, 08:02 AM
Frequently Asked Questions about SOPH
What is SOPH's current stock price?
SOPHiA GENETICS S.A. (SOPH) is currently trading at $4.61 per share. The stock has moved -2.54% today.
What is the analyst price target for SOPH?
The average analyst price target for SOPH is $5.00, based on 1 analyst.
What sector is SOPHiA GENETICS S.A. in?
SOPHiA GENETICS S.A. operates in the Healthcare sector, specifically within the Medical - Healthcare Information Services industry. The company is traded on the NASDAQ exchange.
What is SOPH's market cap?
SOPHiA GENETICS S.A. has a market capitalization of $0.31 billion, making it a small-cap company.
Does SOPH pay dividends?
No, SOPHiA GENETICS S.A. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACIU
AC Immune S.A.
$3.03
Mkt Cap: $0.3B
AGL
Agilon Health, Inc.
$0.73
Mkt Cap: $0.3B
ANRO
Alto Neuroscience, Inc.
$19.98
Mkt Cap: $0.6B
CLLS
Cellectis S.A.
$4.37
Mkt Cap: $0.4B
DH
Definitive Healthcare Corp.
$2.54
Mkt Cap: $0.3B
LRMR
Larimar Therapeutics, Inc.
$3.65
Mkt Cap: $0.3B
NAKA
Kindly MD, Inc.
$0.39
Mkt Cap: $0.1B
NRC
National Research Corporation
$18.70
Mkt Cap: $0.4B
OPRX
OptimizeRx Corporation
$13.51
Mkt Cap: $0.2B
SLP
Simulations Plus, Inc.
$18.75
Mkt Cap: $0.4B
Explore stocks similar to SOPH for comparison